Related references
Note: Only part of the references are listed.Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
Thomas John et al.
CANCER EPIDEMIOLOGY (2022)
Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling
Panupong Mahalapbutr et al.
ACS OMEGA (2022)
Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino [2,3-f]quinazoline derivatives as EGFR inhibitors
Xuemei Qin et al.
BIOORGANIC CHEMISTRY (2021)
Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer
Jianping Huang et al.
BIOORGANIC CHEMISTRY (2019)
Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2
Dengshuai Wei et al.
BIOORGANIC CHEMISTRY (2019)
Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice
Haoru Fan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant
Xuemei Qin et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors
Xuemei Qin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Determination of EGFR Signaling Output by Opposing Gradients of BMP and JAK/STAT Activity
Mariana Fregoso Lomas et al.
CURRENT BIOLOGY (2016)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden et al.
ANNALS OF ONCOLOGY (2013)
Architecture and Membrane Interactions of the EGF Receptor
Anton Arkhipov et al.
CELL (2013)
Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
Erminia Massarelli et al.
LUNG CANCER (2013)
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
Yibing Shan et al.
CELL (2012)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Targeting the function of the HER2 oncogene in human cancer therapeutics
M. M. Moasser
ONCOGENE (2007)
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line
Atsuko Ogino et al.
CANCER RESEARCH (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
